Navigation Links
The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
Date:1/31/2008

e and easily preventable disease among patients hospitalized for acute medical and surgical illnesses. Deep vein thrombosis (DVT) and pulmonary embolism are common manifestations of VTE and can contribute significantly to morbidity and mortality.

Commenting on the study, Doctor Ander Cohen, Co-chair of the ENDORSE Steering Committee, said "ENDORSE findings are important from national heath care perspectives since they allow estimation of both the patient welfare and economic benefits of fully applying evidence based VTE prophylaxis among hospitalised medical and surgical patients. If we want to improve hospital patient outcomes, we urgently need to implement hospital-wide strategies to identify all surgical and medical patients at risk for VTE and improve the use of appropriate prophylaxis to prevent VTE."

Despite International and local guidelines on VTE management, ENDORSE results illustrate clearly that there is a gap between guidelines evidence and practice in the hospital setting throughout the world. Lack of awareness and uncertainty about the prevalence of patients at risk of VTE are among the major reasons accounting for this gap(2),(3)

As highlighted by Doctor Victor Tapson, Co-chair of the ENDORSE Steering Committee: "ENDORSE clearly shows that VTE is a critical safety issue in hospitalized patients, as the majority of them are at risk for VTE. The increased use of prophylaxis in the surgical setting for which the benefits of prophylaxis have been accepted for many years compared with medical setting for which trials and guidelines are more recent, shows that we have to increase physician awareness on the benefits of prophylaxis particularly in medical patient."

About venous thromboembolism (VTE)

Venous thromboembolism is a general term used to describe the formation of a blood clot (thrombus) that blocks a vein. This may occur in any part of the venous system, but the most common manifestations are deep-vein thrombosis (
'/>"/>

SOURCE University of Massachusetts Medical School
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Lancet Publishes Vasogens ACCLAIM Results
2. Vasogens Research Published in European Journal of Neuroscience
3. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
4. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
5. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
6. Medco Chooses AllPoints at Anson in Whitestown, Indiana as Site for the Worlds Largest, Most-Advanced Automated Pharmacy
7. Researchers outline structure of largest nonvirus particle ever crystallized
8. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
9. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
10. MIGENIX to Add 600mg Daily Celgosivir Dose to Phase II Viral Kinetics Study
11. Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... TRIANGLE PARK, N.C. , July 14, 2014 ... focused on cloud-based drug design and development, announced ... development program. The company has been granted supercomputing ... of multiple parasitic targets.  Through ... the Argonne Leadership Computing Facility (ALCF), researchers at ...
(Date:7/14/2014)... July 14, 2014 Throughout this ... across the clinical trials space, representing 38 countries ... series entitled “Optimizing Patient Participation in Clinical Trials. ... off with internationally renowned R&D expert, Ken Getz, ... on Reinventing Drug Development through Patient Centricity. , ...
(Date:7/14/2014)... 14, 2014 Minerva Neurosciences (NASDAQ: ... therapies to treat neuropsychiatric diseases and disorders, today announced ... vice president of finance and chief accounting officer, effective ... senior executive with more than 20 years of experience ... science companies. His background includes the management of compliance ...
(Date:7/14/2014)... San Mateo, CA (PRWEB) July 14, 2014 ... groundbreaking CONNECT patient registry platform, announced that ... Becker muscular dystrophies; the Phelan-McDermid Syndrome International ... primary Nephrotic Syndrome—have been awarded contracts by ... part of the creation of a new ...
Breaking Biology Technology:Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 3Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 4Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 5Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3
... Inc., the,leading developer of stents designed for the ... has closed a $14 million Series,C round of ... Venture,Partners joined with Spray Venture Partners in the ... RiverVest have been appointed to the Tryton,Board of ...
... blood pressure of elderly patients could cut their total,mortality ... by a third,according to a new study presented today ... simultaneously in the New England,Journal of Medicine., LONDON, ... Elderly Trial (HYVET), which is co-ordinated by scientists from,Imperial ...
... discover and develop ... SAN FRANCISCO, March 31 The Immune Tolerance Institute,Inc. ... a Center for Critical Path Immunology to investigate the role ... be managed by,ITI and located initially at Beckman Coulter,s Cellular ...
Cached Biology Technology:Tryton Medical, Inc. Closes $14 Million Financing 2Tryton Medical, Inc. Closes $14 Million Financing 3Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over 2Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over 3Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over 4The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory 2The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory 3
(Date:7/14/2014)... German . , ... development. One classical example is the sequential and rhythmic ... that has been linked to the ticking of an ... now, this patterning process was thought to be determined ... periodically trigger new segment formation. However, this week in ...
(Date:7/14/2014)... MedNet Solutions , a global ... management systems, is pleased to announce that ... on software-as-a-service (SaaS) and Internet-based businesses, has made ... funding, representing the first major outside financing in ... the ongoing growth and development of both MedNet ...
(Date:7/14/2014)... 14, 2014 Research and Markets has ... 2014: Applications for Microfluidic Technologies" report to their offering. ... testing based on microfluidic technology is expected to grow sharply, ... CAGR 2014 - 2019 of 23%. Major diagnostics companies (Alere, ... etc.) have realized the potential of rapid molecular diagnostic testing. ...
Breaking Biology News(10 mins):Timing is not only ticking 2Timing is not only ticking 3Arrowroot Capital Invests $4 Million In MedNet Solutions 2Arrowroot Capital Invests $4 Million In MedNet Solutions 3Applications for Microfluidic Technologies in Point of Care Testing: 2014 Report 2Applications for Microfluidic Technologies in Point of Care Testing: 2014 Report 3
... New evidence suggests that the risk of HIV transmission ... According to a study published in the April ... available online, early infection accounted for nearly half of ... province of Quebec, Canada. , Bluma Brenner, PhD, and ...
... Turn up the white noise, says a team of ... the benefits of noise. Their findings could lead to ... an assistant professor of computer science, Joseph Martin, a ... of biology, are working together to explain the biological ...
... no two brains are alike, they can display a ... sensory input. Scientists at the Max Planck Institute for ... mathematical method to design networks from neural cells which ... their method will assist them in getting closer to ...
Cached Biology News:Risk of HIV transmission highest early in infection 2Noise echoes in cell communications 22 brains -- 1 thought 22 brains -- 1 thought 3
...
Human VEGF R Phycoerythrin Sampler (Cl 89106, 49560, 54733)...
... Beagle serum is collected from fasted Beagle canines ... Available Anticoagulants: N-02: Citrate ... K2EDTA N-08: Potassium Oxalate N-10: ... N-05: ACD N-07: CPD ...
... cDNA Purification Kit is designed to purify double-stranded ... cDNA synthesis and PCR. The process is simple ... to 3 g can be efficiently purified and ... 1) DNA is bound to the Microfilter Cartridge ...
Biology Products: